The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pyrogen testing market reached a value of US$ 1.10 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.04 Billion by 2027, exhibiting at a CAGR of 10.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Pyrogen testing is conducted to detect both endotoxin and non-endotoxin pyrogenic contaminants in aqueous parenteral. It assists in ensuring the safety of the parenteral pharmaceutical product and medical device and avoiding life-threatening diseases and fatal endotoxic shock induced by pyrogenic substances. Some of the commonly utilized methods of pyrogen testing include limulus amebocyte lysate (LAL) test, recombinant factor C (rFC) test, rabbit pyrogen test (RPT), and monocyte activation test (MAT). At present, its demand is escalating across the globe as it is robust, sensitive, and scalable.
The flourishing pharmaceutical and biotechnology industries around the world represent one of the key factors bolstering the growth of the market. Pyrogen testing finds extensive applications in these industries for the safe development and release of infection-free products at a cost-effective price. It is also utilized for determining microbes or the presence of metabolites in drugs during the manufacturing process. Moreover, the testing aids in improving the management of infectious diseases by determining the disease severity, recovery, and sequelae. As a result, it is employed in the production of coronavirus disease (COVID-19) vaccines worldwide. This, along with the increasing prevalence of chronic ailments, such as heart diseases, cancer, and diabetes, is positively influencing the market. Furthermore, leading players are introducing technologically advanced and cost-effective pyrogen testing techniques that provide a more relevant prediction of pyrogenic activity compared to the traditional methods, which is creating a favorable market outlook. Besides this, the launch of the new therapeutics and continuous funding of research and development (R&D) activities by manufacturing companies and governing agencies of numerous countries is acting as another major growth-inducing factor.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pyrogen testing market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on product, test type and application.
Breakup by Product:
Breakup by Test Type:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Ellab A/S, Fujifilm Wako Pure Chemical Corporation (Fujifilm Holdings Corporation), Lonza Group AG, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories LLC (Sotera Health), North American Science Associates Inc., Pacific Biolabs Inc., Sanquin, Thermo Fisher Scientific Inc, Toxikon Corporation and Wuxi Apptec.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Test Type, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Charles River Laboratories International Inc., Ellab A/S, Fujifilm Wako Pure Chemical Corporation (Fujifilm Holdings Corporation), Lonza Group AG, Merck KGaA, Microcoat Biotechnologie GmbH, Nelson Laboratories LLC (Sotera Health), North American Science Associates Inc., Pacific Biolabs Inc., Sanquin, Thermo Fisher Scientific Inc, Toxikon Corporation and Wuxi Apptec.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Home Healthcare Market by Product (Therapeutic Products, Testing, Screening, and Monitoring Products, Mobility Care Products), Service (Skilled Nursing, Rehabilitation Therapy, Hospice & Palliative Care, Unskilled Care, Respiratory Therapy, Infusion Therapy, Pregnancy Care), Indication (Cancer, Respiratory Diseases, Movement Disorders, Cardiovascular Diseases & Hypertension, Pregnancy, Wound Care, Diabetes, Hearing Disorders, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at